214 related articles for article (PubMed ID: 25052698)
1. A phase 1 dose escalation study of idarubicin combined with methotrexate, vindesine, and prednisolone for untreated elderly patients with primary central nervous system lymphoma. The GOELAMS LCP 99 trial.
Olivier G; Clavert A; Lacotte-Thierry L; Gardembas M; Escoffre-Barbe M; Brion A; Cumin I; Legouffe E; Solal-Celigny P; Chabin M; Ingrand P; Colombat P; Delwail V
Am J Hematol; 2014 Nov; 89(11):1024-9. PubMed ID: 25052698
[TBL] [Abstract][Full Text] [Related]
2. Primary central nervous system lymphoma: Phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated fractionation radiation therapy after chemotherapy.
Dabaja BS; McLaughlin P; Ha CS; Pro B; Meyers CA; Seabrooke LF; Wilder RB; Kyritsis AP; Preti HA; Yung WK; Levin V; Cabanillas F; Cox JD
Cancer; 2003 Sep; 98(5):1021-8. PubMed ID: 12942571
[TBL] [Abstract][Full Text] [Related]
3. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial.
Thiel E; Korfel A; Martus P; Kanz L; Griesinger F; Rauch M; Röth A; Hertenstein B; von Toll T; Hundsberger T; Mergenthaler HG; Leithäuser M; Birnbaum T; Fischer L; Jahnke K; Herrlinger U; Plasswilm L; Nägele T; Pietsch T; Bamberg M; Weller M
Lancet Oncol; 2010 Nov; 11(11):1036-47. PubMed ID: 20970380
[TBL] [Abstract][Full Text] [Related]
4. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma.
Soussain C; Suzan F; Hoang-Xuan K; Cassoux N; Levy V; Azar N; Belanger C; Achour E; Ribrag V; Gerber S; Delattre JY; Leblond V
J Clin Oncol; 2001 Feb; 19(3):742-9. PubMed ID: 11157026
[TBL] [Abstract][Full Text] [Related]
5. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639
[TBL] [Abstract][Full Text] [Related]
6. [MTX-HOPE (methotrexate, hydrocortisone, vincristine, sobuzoxane, and etoposide) as a low-dose salvage chemotherapy for recurrent or refractory non-Hodgkin's lymphoma].
Tsunoda S; Kobayashi H; Inoue K; Izumi T; Akutsu M; Katano S; Ueda T; Shirai T; Masuda Y; Ohmine K; Nagashima T; Ueda M; Takagi S; Muroi K; Ozawa K; Kano Y
Gan To Kagaku Ryoho; 2007 Jun; 34(6):885-9. PubMed ID: 17565251
[TBL] [Abstract][Full Text] [Related]
7. Primary central nervous system lymphoma (PCNSL) in immunocompetent adults: analysis of a retrospective series of patients treated using idarubicin-containing regimen and radiotherapy.
Vigliotti ML; Dell'Olio M; La Sala A; Romano G; Tartarone A; Mele G; Musto C; Carella AM; Di Renzo N
Hematol J; 2004; 5(5):453-5. PubMed ID: 15448676
[No Abstract] [Full Text] [Related]
8. The development of targeted chemotherapy for CNS lymphoma-a pilot study of the IDARAM regimen.
Moreton P; Morgan GJ; Gilson D; Smith GM; McVerry BA; Davies JM; Mackie MJ; Bolam S; Jalihal SS; Howard MR; Parapia LA; Williams AT; Child JA;
Cancer Chemother Pharmacol; 2004 Apr; 53(4):324-8. PubMed ID: 14704830
[TBL] [Abstract][Full Text] [Related]
9. High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study.
Illerhaus G; Marks R; Müller F; Ihorst G; Feuerhake F; Deckert M; Ostertag C; Finke J
Ann Oncol; 2009 Feb; 20(2):319-25. PubMed ID: 18953065
[TBL] [Abstract][Full Text] [Related]
10. [Salvage therapy for recurrent or refractory non-Hodgkin's lymphoma with etoposide, methotrexate, vindesine and prednisolone (EMVP)].
Sano F; Koike M; Nakamura K; Wakayama T; Kunika N; Kubomatsu Y; Katoh M; Chisa M; Hasegawa S; Takahashi M
Gan To Kagaku Ryoho; 1992 Dec; 19(14):2389-93. PubMed ID: 1463345
[TBL] [Abstract][Full Text] [Related]
11. High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study.
Bengala C; Danesi R; Guarneri V; Pazzagli I; Donati S; Favre C; Fogli S; Biadi O; Innocenti F; Del Tacca M; Mariani M; Conte PF
Bone Marrow Transplant; 2003 Feb; 31(4):275-80. PubMed ID: 12621462
[TBL] [Abstract][Full Text] [Related]
12. Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients.
Toffoli G; Sorio R; Aita P; Crivellari D; Corona G; Bearz A; Robieux I; Colussi AM; Stocco F; Boiocchi M
Clin Cancer Res; 2000 Jun; 6(6):2279-87. PubMed ID: 10873078
[TBL] [Abstract][Full Text] [Related]
13. Treatment for primary CNS lymphoma: the next step.
Abrey LE; Yahalom J; DeAngelis LM
J Clin Oncol; 2000 Sep; 18(17):3144-50. PubMed ID: 10963643
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group.
Hoang-Xuan K; Taillandier L; Chinot O; Soubeyran P; Bogdhan U; Hildebrand J; Frenay M; De Beule N; Delattre JY; Baron B;
J Clin Oncol; 2003 Jul; 21(14):2726-31. PubMed ID: 12860951
[TBL] [Abstract][Full Text] [Related]
15. Multicenter Phase II study of CyclOBEAP regimen for elderly patients with poor-prognosis aggressive lymphoma.
Niitsu N; Okamoto M; Kohori M; Aoki S; Miura I; Hirano M
Hematol Oncol; 2006 Dec; 24(4):220-6. PubMed ID: 16958147
[TBL] [Abstract][Full Text] [Related]
16. Dose escalation study on oxaliplatin and capecitabine (Xeloda) in patients with advanced solid tumors.
Kakolyris S; Souglakos J; Kouroussis C; Androulakis N; Samonis G; Vardakis N; Amarantidis K; Agelaki S; Mavroudis D; Xenidis N; Georgoulias V
Oncology; 2004; 66(4):253-9. PubMed ID: 15218291
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with advanced solid tumors: parallel topotecan escalation in two fixed platinum dosing schemes.
Pentheroudakis G; Briasoulis E; Karavassilis V; Mauri D; Tzamakou E; Rammou D; Pavlidis N
Chemotherapy; 2005 May; 51(2-3):154-61. PubMed ID: 15886476
[TBL] [Abstract][Full Text] [Related]
18. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy.
Pels H; Schmidt-Wolf IG; Glasmacher A; Schulz H; Engert A; Diehl V; Zellner A; Schackert G; Reichmann H; Kroschinsky F; Vogt-Schaden M; Egerer G; Bode U; Schaller C; Deckert M; Fimmers R; Helmstaedter C; Atasoy A; Klockgether T; Schlegel U
J Clin Oncol; 2003 Dec; 21(24):4489-95. PubMed ID: 14597744
[TBL] [Abstract][Full Text] [Related]
19. Modified ProMACE-MOPP hybrid regimen with moderate-dose methotrexate for patients with primary CNS lymphoma.
Yamanaka R; Morii K; Shinbo Y; Takeuchi S; Tamura T; Hondoh H; Takahashi H; Onda K; Takahashi H; Tanaka R
Ann Hematol; 2005 Jul; 84(7):447-55. PubMed ID: 15747120
[TBL] [Abstract][Full Text] [Related]
20. MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas.
Ferreri AJ; Dell'Oro S; Foppoli M; Bernardi M; Brandes AA; Tosoni A; Montanari M; Balzarotti M; Spina M; Ilariucci F; Zaja F; Stelitano C; Bobbio F; Corazzelli G; Baldini L; Ponzoni M; Picozzi P; Caligaris Cappio F; Reni M
Neurology; 2006 May; 66(9):1435-8. PubMed ID: 16682682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
